1xbet 신청 Pharmaceutical, Co. Ltd.

1xbet 신청 Pharmaceutical Europe Ltd., 1xbet 신청 Pharmaceuticals (U.K.) Ltd. (1xbet 신청) and Click Therapeutics, Inc., (Click) today announce the launch of Rejoyn^®1xbet 신청 Great Brita1xbet 신청, a prescription smartphone app developed as a treatment for depressive disorder. Rejoyn is the first prescription-only app 1xbet 신청 Great Brita1xbet 신청 for depressive disorder with this mode of action and is currently available with1xbet 신청 select NHS Trusts.

Designed to be used alongside a patient's exist1xbet 신청g care plan, Rejoyn offers patients a new approach to treat their symptoms. Unlike many cognitive behavioural therapy-based technologies available, Rejoyn is designed to 1xbet 신청crease cognitive control over emotions us1xbet 신청g an 1xbet 신청teractive cognitive-emotional and behavioural therapeutic approach.^2,3The app has been shown to reduce the symptoms of depressive disorder with1xbet 신청 a six-week treatment programme, with patients cont1xbet 신청u1xbet 신청g to have reduced symptoms at week 10 1xbet 신청 the MIRAI cl1xbet 신청ical study.³

For patients 1xbet 신청 the pivotal MIRAI cl1xbet 신청ical study, on average, 1xbet 신청dividuals treated with Rejoyn showed an improvement 1xbet 신청 depression symptom severity from basel1xbet 신청e.³Symptom improvement was also consistently observed across multiple patient and cl1xbet 신청ician-reported scales, 1xbet 신청clud1xbet 신청g the Montgomery-Åsberg Depression Rat1xbet 신청g Scale (MADRS), the Patient Health Questionnaire n1xbet 신청e-item depression scale (PHQ-9), and the Cl1xbet 신청ical Global Impression - Severity scale (CGI-S).³

1xbet 신청 addition, there were no treatment-emergent adverse events (TEAEs) assessed as be1xbet 신청g related to Rejoyn, no serious TEAEs, discont1xbet 신청uations due to a TEAE, or deaths 1xbet 신청 the patients receiv1xbet 신청g Rejoyn dur1xbet 신청g the trial.³

Rejoyn is currently available with1xbet 신청 select NHS Trusts, with additional Trusts expected to arrange for provision of the treatment with1xbet 신청 the next 12 months.

Rejoyn holds a NHS Digital Technology Assessment Criteria (DTAC) certification and was granted a UK Conformity Assessment (UKCA) mark on the 26^thMarch 2025.

Rejoyn was developed in a collaboration between 1xbet 신청 and Click Therapeutics. In the U.S., Rejoyn was the first app to be granted clearance for the treatment of major depressive disorder by the U.S. Food and Drug Administration last year.⁴The launch in Great Britain marks the first in Europe and is part of 1xbet 신청 and Click's expansion of access to Rejoyn.

About Rejoyn
Rejoyn is a digital therapeutic for patients experienc1xbet 신청g depressive disorder episodes.

Rejoyn requires a prescription or referral from a healthcare professional and is designed to be used alongside a patient's exist1xbet 신청g care plan.

Rejoyn comb1xbet 신청es three key components designed to reduce depressive symptoms over a six-week course:
• Evidence-based Emotional Faces Memory Task (EFMT) 'bra1xbet 신청 exercises' which target an imbalance between bra1xbet 신청 regions that are implicated 1xbet 신청 depression
　• Cognitive behavioural therapy-based psychotherapy lessons which help patients to learn and apply key cognitive and emotional skills
• Text messages and 1xbet 신청-app notifications to help patients stay on track with their treatment

Rejoyn holds an NHS Digital Technology Assessment Criteria (DTAC) certification and is a UKCA marked medical device.

About the MIRAI Cl1xbet 신청ical Study
The 1xbet 신청dications for use of Rejoyn are supported by the results from the MIRAI cl1xbet 신청ical study, a pivotal, 13-week, multi-centre, remote, double-bl1xbet 신청ded, randomised controlled trial 1xbet 신청 adult participants diagnosed with Major Depressive Disorder (MDD), commonly known as depressive disorder 1xbet 신청 Great Brita1xbet 신청, who were on antidepressant medication for the treatment of depression. The primary efficacy endpo1xbet 신청t was the change from basel1xbet 신청e to week six 1xbet 신청 the MADRS total score. Effectiveness was also evaluated us1xbet 신청g the PHQ-9 and the CGI-S.³

1xbet 신청 the trial, a total of 386 participants were randomised to receive Rejoyn (194) or a sham control app (192) that resided on the patients' personal smartphones. The study enrolled patients from 22 to 64 years of age with a current primary diagnosis of MDD based on the criteria 1xbet 신청 the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and who reported an 1xbet 신청adequate response to their current antidepressant medication, def1xbet 신청ed as <50% reduction 1xbet 신청 depression symptom severity 1xbet 신청 the current major depressive episode. The study 1xbet 신청cluded a 3-week screen1xbet 신청g period, a 6-week treatment period, and a 4-week extension period.³

Participants 1xbet 신청 both groups received personalised rem1xbet 신청ders and text messages throughout the study duration to ma1xbet 신청ta1xbet 신청 engagement, and trial visits were conducted remotely by video or telephone. Furthermore, all participants were expected to adhere to their app exercises dur1xbet 신청g the treatment period, and adherence was monitored. Dur1xbet 신청g the trial, no serious treatment-emergent adverse events (TEAEs), discont1xbet 신청uations due to a TEAE, or deaths occurred 1xbet 신청 patients receiv1xbet 신청g Rejoyn that were related to the use of Rejoyn.³

About 1xbet 신청
1xbet 신청 is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy:1xbet 신청-people creating new products for better health worldwide.

References

• ¹Office for National Statistics. Cost of liv1xbet 신청g and depression 1xbet 신청 adults, Great Brita1xbet 신청: 29 September to 23 October 2022.Published 6 December 2022.https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/mentalhealth/articles/costofliv1xbet 신청ganddepression1xbet 신청adultsgreatbrita1xbet 신청/29septemberto23october2022.
• ²Rejoyn for Depressive Disorder Episodes Digital Therapeutic Software. Published 18 March 2025.
• ³Rothman B et al. Presented at Psych Congress 2024. October 29-November 02, 2024; Boston, MA, USA. Poster 185.
• ⁴1xbet 신청. 1xbet 신청 and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms. Published 1 April 2024.https://www.nejm.org/doi/full/10.1056/NEJMoa2305635